Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Predictive value of pre-infusion tumor growth rate for the occurrence and severity of CRS and ICANS in lymphoma under CAR T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Quell C, Bücklein VL, Ingenerf M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Ann Hematol. 2024 Jan;103(1):259-268. doi: 10.1007/s00277-023-05507-9. Epub 2023 Oct 20. Ann Hematol. 2024. PMID: 37861736
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy.
Winkelmann M, Blumenberg V, Rejeski K, Bücklein VL, Ruzicka M, Unterrainer M, Schmidt C, Dekorsy FJ, Bartenstein P, Ricke J, von Bergwelt-Baildon M, Subklewe M, Kunz WG. Winkelmann M, et al. Eur J Nucl Med Mol Imaging. 2023 Apr;50(5):1406-1413. doi: 10.1007/s00259-022-06075-2. Epub 2022 Dec 14. Eur J Nucl Med Mol Imaging. 2023. PMID: 36513818
Potential synergy between radiotherapy and CAR T-cells - a multicentric analysis of the role of radiotherapy in the combination of CAR T cell therapy.
Fan J, Adams A, Sieg N, Heger JM, Gödel P, Kutsch N, Kaul D, Teichert M, von Tresckow B, Bücklein V, Goesmann G, Li M, Struve N, Trommer M, Linde P, Rosenbrock J, Celik E, Penack O, Stuschke M, Subklewe M, Belka C, von Bergwelt-Baildon M, Borchmann P, Marnitz S, Baues C. Fan J, et al. Radiother Oncol. 2023 Jun;183:109580. doi: 10.1016/j.radonc.2023.109580. Epub 2023 Feb 25. Radiother Oncol. 2023. PMID: 36842663
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board.
Dorman K, Zhang D, Heinrich K, Reeh L, Weiss L, Haas M, Beyer G, Rössler D, Goni E, Renz BW, D'Haese JG, Kunz WG, Seidensticker M, Corradini S, Niyazi M, Ormanns S, Kumbrink J, Jung A, Klauschen F, Werner J, Mayerle J, von Bergwelt-Baildon M, Boeck S, Heinemann V, Westphalen CB. Dorman K, et al. Target Oncol. 2023 Mar;18(2):257-267. doi: 10.1007/s11523-023-00950-0. Epub 2023 Feb 28. Target Oncol. 2023. PMID: 36853374 Free PMC article.
Identifying Early Infections in the Setting of CRS With Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL.
Rejeski K, Blumenberg V, Iacoboni G, Lopez-Corral L, Kharboutli S, Hernani R, Petrera A, Müller N, Hildebrand F, Frölich L, Karschnia P, Schmidt C, Cordas Dos Santos DM, Piñana JL, Müller F, Martin AA, Dreyling M, von Bergwelt-Baildon M, Barba P, Subklewe M, Bücklein VL. Rejeski K, et al. Hemasphere. 2023 Apr 5;7(4):e858. doi: 10.1097/HS9.0000000000000858. eCollection 2023 Apr. Hemasphere. 2023. PMID: 37038465 Free PMC article.
Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
Weiss L, Heinrich K, Zhang D, Dorman K, Rühlmann K, Hasselmann K, Klauschen F, Kumbrink J, Jung A, Rudelius M, Mock A, Ormanns S, Kunz WG, Roessler D, Beyer G, Corradini S, Heinzerling L, Haas M, von Bergwelt-Baildon M, Boeck S, Heinemann V, Westphalen CB. Weiss L, et al. J Cancer Res Clin Oncol. 2023 Sep;149(11):8225-8234. doi: 10.1007/s00432-023-04741-y. Epub 2023 Apr 16. J Cancer Res Clin Oncol. 2023. PMID: 37062035 Free PMC article.
349 results